歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

已收盘 06-12 16:08:21

10.020

-0.030

-0.30%

最高10.240	最低9.800	成交量152.57万
今开10.070	昨收10.050	日振幅4.38%
总市值106.31亿	流通市值106.31亿	总股本10.61亿
成交额1,528万	换手率0.14%	流通股本10.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":10.02,"timestamp":1781251701004,"preClose":10.05,"halted":0,"volume":1525667,"delay":0,"changeRate":-0.0029850746268657844,"floatShares":1061000000,"shares":1061000000,"eps":-0.42868672125367285,"marketStatus":"已收盘","change":-0.03,"latestTime":"06-12 16:08:21","open":10.07,"high":10.24,"low":9.8,"amount":15284514,"amplitude":0.043781,"askPrice":10.04,"askSize":2000,"bidPrice":10.02,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.43436238981390796,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":10.05,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":0.616664,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1122549517","title":"歌礼制药-B6月12日回购20万股，总额约201.18万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122549517","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122549517?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:32","pubTimestamp":1781260364,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年6月12日发布公告，称当日于香港联交所场内回购200,000股普通股，约占公司已发行股本的0.0188%。本次回购每股价格介乎9.93港元至10.19港元，总涉资约2,011,760港元。此外，回购授权于2025年5月22日获股东大会通过，授权总数为96,284,628股，公司已累计在香港联交所及其他交易所购回8,086,000股，占授权通过当日已发行股份数目的0.8391%。公司在公告中确认，本次回购已遵守香港联交所上市规则及相关法律法规，并由公司秘书钟明辉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B6月12日回购20万股，总额约201.18万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107071582","title":"歌礼制药-B于6月11日回购200,000股股份，耗资约196.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107071582","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107071582?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:32","pubTimestamp":1781173972,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年6月11日发布公告，披露其在香港联交所场内进行了股份回购等事项。截至当日，公司已发行股份总数为1,061,370,845股，库藏股数为7,084,210股，合计1,068,455,055股。据公告，购回授权的决议于2025年5月22日通过，授权总规模为96,284,628股。截至目前，公司已在香港联交所及其他证券交易所合计回购7,886,000股，占购回授权通过当日已发行股本的0.8184%。公司确认本次回购行为符合香港联交所证券上市规则及相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B于6月11日回购200,000股股份，耗资约196.69万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642228549","title":"歌礼制药-B(01672)6月11日斥资196.69万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642228549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642228549?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:30","pubTimestamp":1781173810,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，该公司于2026年6月11日斥资196.69万港元回购20万股股份，每股回购价格为9.63-10.11港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1515","01477","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114959740","title":"歌礼制药-B于6月10日回购20万股，涉资约199.96万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114959740","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114959740?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:32","pubTimestamp":1781087552,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年6月10日公告，显示当日回购普通股合计200,000股，约占公司已发行股本的0.0188%。本次回购每股价格介乎每股9.75港元至10.15港元，总金额为1,999,590港元。公司披露，截至2026年6月10日，其已发行股本为1,061,370,845股，库藏股为7,084,210股，合计1,068,455,055股。该批回购股份尚未完成注销，故目前公司已发行股本及库藏股数维持不变。公告并确认，本次回购已遵照香港联合交易所有限公司证券上市规则及相关法律法规的规定办理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B于6月10日回购20万股，涉资约199.96万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440659","title":"歌礼制药-B(01672)6月10日斥资199.96万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642440659?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:28","pubTimestamp":1781087318,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，该公司于2026年6月10日斥资199.96万港元回购20万股股份，每股回购价格为9.75-10.15港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","01477","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113268805","title":"歌礼制药-B：6月9日回购20万股股份，耗资约201.40万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113268805","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113268805?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:16","pubTimestamp":1781000199,"startTime":"0","endTime":"0","summary":"歌礼制药-B  于2026年6月9日公告，公司当天在香港联交所场内回购普通股20万股，占已发行股本约0.0188%。回购价格介乎每股9.80港元至10.28港元，合计支付约2,013,990港元。回购授权的决议于2025年5月22日获通过，可回购股份总数为96,284,628股，目前已回购7,486,000股，剩余可回购股份为88,798,628股。公司确认本次回购符合香港联合交易所有限公司证券上市规则及当地适用法规的相关要求。本次公告由公司秘书鍾明輝签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：6月9日回购20万股股份，耗资约201.40万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115806178","title":"歌礼制药-B：6月8日回购20万股，涉资约200.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115806178","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115806178?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:56","pubTimestamp":1780916192,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672)于2026年6月8日公告，公司当日于香港联交所场内回购20万股普通股，占已发行股本约0.0188%。本次回购每股价格介乎9.88港元至10.26港元，总金额约200.80万港元。\n回购完成后，公司已发行股本维持在1,061,370,845股，库藏股数为7,084,210股。本次回购基于2025年5月22日通过的购回授权，该授权允许公司回购共计96,284,628股。截至目前，公司已累计回购7,286,000股，占授权通过当日已发行股本约0.7561%。\n公司确认已遵守香港联交所上市规则及相关法律规定。公告由公司秘书钟明辉签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：6月8日回购20万股，涉资约200.80万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641048632","title":"歌礼制药-B(01672)6月8日斥资200.8万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641048632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641048632?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:54","pubTimestamp":1780916097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月8日，该公司斥资200.8万港元回购20万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","01477","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150875195","title":"歌礼制药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1150875195","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150875195?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:10","pubTimestamp":1780650613,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司在公告中表示，公司董事会拟于2026年6月29日举行的股东周年大会上寻求一般性授权，可于授权获准当日已发行股份总数的10%范围内回购股份。董事会认为回购计划符合公司及股东的最佳利益。董事会表示，在获得上述回购授权后，将密切关注市场情况，有序开展购回安排，并在适用法例和监管要求范围内执行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1133045149","title":"歌礼制药-B：6月4日回购20万股，耗资约202.62万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133045149","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133045149?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:31","pubTimestamp":1780572711,"startTime":"0","endTime":"0","summary":"2026年6月4日，歌礼制药有限公司发布翌日报表，披露最新股份回购情况。公告显示，公司于2026年6月4日于香港联交所场内回购股份200,000股，约占已发行股本的0.0188%。回购价格介乎每股9.8港元至10.31港元，合计付出约202.62万港元。本次回购后，公司已发行股本仍为1,061,370,845股，库藏股数量维持在7,084,210股。截至目前，已在交易所累计回购6,886,000股，占授权通过当日已发行股本约0.7146%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：6月4日回购20万股，耗资约202.62万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640542861","title":"歌礼制药-B(01672)6月4日耗资约202.62万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640542861","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640542861?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:28","pubTimestamp":1780572500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2026年6月4日耗资约202.62万港元回购20万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01477","BK1574","01672","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145435342","title":"歌礼制药-B：6月3日回购20万股，耗资约201.31万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145435342","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145435342?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:31","pubTimestamp":1780479112,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年6月3日公告，当日通过香港联交所场内回购普通股20万股，约占公司已发行股本的0.0188%。回购价格区间为每股9.82港元至10.25港元，合计耗资约201.31万港元。根据2025年5月22日通过的回购授权，公司可回购股份总数为96,284,628股，截至目前已累计回购6,686,000股，占授权通过当日公司已发行股本约0.6938%。公司确认本次回购符合香港联交所上市规则和相关法规要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：6月3日回购20万股，耗资约201.31万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177060361","title":"歌礼制药-B6月2日回购20万股股份，总涉资约205.65万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177060361","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177060361?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:16","pubTimestamp":1780395366,"startTime":"0","endTime":"0","summary":"2026年6月2日，歌礼制药有限公司公告称，当日于香港联交所回购普通股200,000股，约占已发行股本的0.0188%。本次回购每股价格介乎每股9.98港元至10.54港元，总涉资约205.65万港元。公司指出，此次回购基于其于2025年5月22日获得通过的购回授权，授权回购股份总数为9,628.46万股，目前已根据该授权累计回购6,486,000股，占授权通过当日已发行股本的0.6731%。公司同时确认已遵守香港联交所主板上市规则及相关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B6月2日回购20万股股份，总涉资约205.65万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640914694","title":"歌礼制药-B(01672)6月2日耗资205.652万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640914694","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640914694?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:15","pubTimestamp":1780395335,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2026年6月2日耗资205.652万港元回购20万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1191","BK1161","01477","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110164146","title":"歌礼制药-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1110164146","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110164146?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:42","pubTimestamp":1780306945,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年6月1日公布了截至2026年5月31日止的月度证券变动情况。报告显示，公司法定股本总额维持700,000美元不变，注册股本数量为7,000,000,000股普通股，每股面值0.0001美元。关于购股权计划，2019年6月6日通过的购股权计划本月注销150,000份股份期权，截至报告期末剩余6,358,128份；受此计划限制，可潜在发行或转让的普通股数量为2,845,628股。截至2026年5月31日，公司股本数量保持不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02259","02685","02155","09993","02172","09869","06990","03986","02142","02565","06681","06613","01592","01477","01516","00177","02506","09626","02609","00117","02714","06603","06955","02587","09926","01919","00107","00981","01473","08547","00384","00165","02050","00004","00152","00199","02418","00087","06699","09880","09866","01211","00909","00008","02598","06110","00081","01672","03888","02291"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2637803207","title":"港股异动 | 歌礼制药-B(01672)早盘涨超5% GIC持股比例升至7% ASC30美国II期研究已完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637803207","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637803207?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:57","pubTimestamp":1779332279,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘涨超5%，截至发稿，涨4.04%，报15.45港元，成交额1634.76万港元。增持后，GIC持股数量增至7480.8万股，持股比例升至7%。值得注意的是，ASC30用于治疗2型糖尿病的13周美国II期研究已完成入组，预计将于2026年第三季度获得该项治疗2型糖尿病的II期研究的顶线数据。在业内看来，ASC30减重数据优越，安全性良好，且分子专利已获美国授权，BD潜力较大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","01477","VXUS","BK4588","GIC","BK1515","BK1191","01672","BK1574","BK4104","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","IE00B543WZ88.USD","BK1600","SG9999014674.SGD","06978","BK1583","IE00BPRC5H50.USD","LU0348767384.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0348825331.USD","LU0417516902.SGD","02162","BK1574","02268","BK1191","LU1969619763.USD","LU2476274308.USD","159992","BK1593","LU0561508036.HKD","09939","LU0634319403.HKD","01672","BK1587","LU0348783233.USD","BK1515","LU0348827113.USD","BK1141","LU2328871848.SGD","LU2778985437.USD","LU2476274720.SGD","09926","LU1720050803.USD","LU2399975544.HKD","09995","LU0348735423.USD","LU0348784397.USD","06855","LU1961090484.USD","LU1794554557.SGD","LU2488822045.USD","LU0417516738.SGD","BK1161","LU0348766576.USD","159938","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021349","title":"GIC Private Limited增持歌礼制药-B(01672)12.2万股 每股作价16.612港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021349","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634021349?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:07","pubTimestamp":1778584055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月7日，GIC Private Limited增持歌礼制药-B(01672)12.2万股，每股作价16.612港元，总金额约为202.67万港元。增持后最新持股数目为7480.8万股，最新持股比例为7.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1574","01477","BK1191","BK1161","BK4104","GIC","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634015154","title":"花旗：中国医疗保健行业基本面持续改善 首选药明康德(02359)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2634015154","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634015154?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:54","pubTimestamp":1778489665,"startTime":"0","endTime":"0","summary":"创新正获得回报，授权交易预付款及里程碑付款带动盈利，创新药销售加速，而CXO订单量更创下历史新高。展望未来，该行预期将有一系列短期催化剂，包括ASCO 2026年数据发布、授权交易势头持续、4月14日药品价格改革后续、CXO指引可能上调，以及市场整合加速利好医疗科技、服务及药房领导者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B031HY20.USD","02359","LU2242644610.SGD","LU1997245177.USD","LU0072461881.USD","LU0516423174.USD","LU0314109678.HKD","LU1951186391.HKD","01276","LU0170899867.USD","IE0008369823.USD","01672","IE00B5MMRT66.SGD","LU1366192091.USD","01093","02269","LU0203347892.USD","LU0326950275.SGD","LU1008478684.HKD","LU2488822045.USD","LU1023057109.AUD","LU0516422366.SGD","LU1719994722.HKD","LU2360032135.SGD","IE00BZ08YT58.USD","LU0980610538.SGD","SG9999004220.SGD","LU0572944931.SGD","BK1191","LU2125154935.USD","LU2045819591.USD","603259","LU2417539215.USD","LU0359202008.SGD","LU0310800965.SGD","LU0979878070.USD","LU0455707207.USD","BK4504","LU2097828714.EUR","LU1242518857.USD","LU0315179316.USD","LU1506573853.SGD","LU1997244956.HKD","LU1226287792.SGD","01801","BK1515","BK1141","LU0098860793.USD","LU1226288253.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":-0.0157},{"period":"1month","weight":-0.4053},{"period":"3month","weight":-0.3255},{"period":"6month","weight":-0.3079},{"period":"1year","weight":0.142},{"period":"ytd","weight":-0.1176}],"compareEarnings":[{"period":"1week","weight":-0.0398},{"period":"1month","weight":-0.0797},{"period":"3month","weight":-0.0478},{"period":"6month","weight":-0.0665},{"period":"1year","weight":-0.0048},{"period":"ytd","weight":-0.0539}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.058155},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}